Rupert Vessey - 31 Dec 2021 Form 4 Insider Report for BRISTOL MYERS SQUIBB CO (BMY)

Role
EVP, Research & Early Dev.
Signature
/s/ Lisa A. Atkins, attorney-in-fact for Rupert Vessey
Issuer symbol
BMY
Transactions as of
31 Dec 2021
Net transactions value
-$1,436,108
Form type
4
Filing time
04 Jan 2022, 17:19:49 UTC
Previous filing
17 Dec 2021
Next filing
08 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BMY Common Stock, $0.10 par value Options Exercise $0 +45,029 +141% $0.000000 76,989 31 Dec 2021 Direct F1
transaction BMY Common Stock, $0.10 par value Tax liability $1,436,108 -23,033 -30% $62.35 53,956 31 Dec 2021 Direct F2
holding BMY Common Stock, $0.10 par value 627 31 Dec 2021 BMS Savings and Investment Program F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMY Restricted Stock Units Options Exercise $0 -45,029 -100% $0.000000* 0 31 Dec 2021 Common Stock, $0.10 par value 45,029 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 In connection with the Merger, all outstanding Celgene Corporation Performance Share Unit awards were assumed by BMS and converted into a restricted unit award. The restricted stock unit reported on this Form 4 vests in full on December 31, 2021, which is the end of the original performance period associated with the original Performance Share Unit award.
F2 Shares withheld for payment of taxes upon vesting of awards.
F3 Based on recent 401(k) plan statement.
F4 Each restricted stock unit converts into one share of common stock upon vesting.